autologous PD-1 gene-deleted T-lymphocytes

Autologous PD-1 gene-deleted T-lymphocytes is an adoptive cell therapy consisting of patient-derived T cells that have been genetically engineered to knock out or delete the programmed cell death protein 1 (PD-1) gene, typically using CRISPR/Cas9 or base-editing technologies. By disrupting the PD-1 gene, these T-lymphocytes are rendered resistant to PD-L1-mediated immunosuppression within the tumor microenvironment, thereby enhancing their cytotoxic activity and proliferation against tumor cells. This cell therapy is primarily being investigated for the treatment of solid tumors, including advanced or metastatic non-small cell lung cancer (NSCLC).

Other names

PD-1 deletion gene T lymphocytesPD1 deletion gene T lymphocytesPD 1 deletion gene T lymphocytesPD-1 gene-deleted autologous T-lymphocytesPD1 gene-deleted autologous T-lymphocytesPD 1 gene-deleted autologous T-lymphocytesPD-1-deficient T-lymphocytesPD1-deficient T-lymphocytesPD 1-deficient T-lymphocytesautologous PD-1 knockout T-lymphocytes